Home › Funds › Parkman Healthcare Partners LLC › AMRX
Parkman Healthcare Partners LLC position in AMRX
AMNEAL PHARMACEUTICALS INC · Health Care
Parkman Healthcare Partners LLC reported holding 541,190 shares of AMRX (AMNEAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$9.4M, representing 0.96% of its reported portfolio and ranking #43 among its reported holdings. Parkman Healthcare Partners LLC has disclosed AMRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's AMRX position evolved
Parkman Healthcare Partners LLC first disclosed a stake in AMRX in Q1 2026 at 300,752 shares (US$3.7M). The position peaked in Q2 2026 at 541,190 shares, worth US$9.4M. Across 2 filings, Parkman Healthcare Partners LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 541,190 shares valued at US$9.4M — an increase of 240,438 shares quarter over quarter.. Notable position changes include a 80% increase in Q2 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 300.75K | $3.74M | New |
| Q2 2026 | 541.19K | $9.37M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMRX and 13F data
AMRX (AMNEAL PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in AMRX — the largest reported positions include TPG GP A, LLC (US$213.4M), Rubric Capital Management LP (US$176.0M), Nantahala Capital Management, LLC (US$39.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMRX
- TPG GP A, LLC 12.33M sh · $213.41M · Q2 2026
- Rubric Capital Management LP 10.17M sh · $176.02M · Q2 2026
- Nantahala Capital Management, LLC 2.27M sh · $39.27M · Q2 2026
- Westshore Wealth, LLC 1.37M sh · $23.65M · Q2 2026
- BlackBarn Capital Partners LP 1.30M sh · $22.50M · Q2 2026
- Penn Capital Management Company, LLC 1.18M sh · $20.48M · Q2 2026
- TUCKER ASSET MANAGEMENT LLC 1.01M sh · $17.50M · Q2 2026
- Phocas Financial Corp. 819.48K sh · $14.19M · Q2 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held AMRX?
Parkman Healthcare Partners LLC has disclosed AMRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Parkman Healthcare Partners LLC's current position in AMRX?
As of Q2 2026, Parkman Healthcare Partners LLC holds 541.19K shares of AMRX (AMNEAL PHARMACEUTICALS INC), valued at $9.37M, representing 0.96% of its reported portfolio and ranking #43.
Has Parkman Healthcare Partners LLC been buying or selling AMRX?
In the latest 13F filing (Q2 2026), Parkman Healthcare Partners LLC increased its position in AMRX. The position peaked in Q2 2026 at 541.19K shares.
Which other funds hold AMRX?
Other major institutional holders of AMRX include TPG GP A, LLC, Rubric Capital Management LP, Nantahala Capital Management, LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.